Groundbreaking Transparency Application that Anonymizes Patient Data in Clinical Trials Launched by TrialAssure
CANTON, Mich., Feb. 27, 2019 /PRNewswire/ -- TrialAssure® – a leading, global software company focused on developing clinical trial transparency tools – announced today the limited release of ANONYMIZE DS, an all-new software-as-a-service (SaaS) application that allows sponsors to anonymize clinical trial data automatically. This exclusive application will be discussed during a presentation this afternoon by Zach Weingarden at the PhUSE Connect 2019 Data-Driven Science conference in Baltimore, Maryland.
"In order to share data, it has to be done in a way that protects patient privacy. TrialAssure's ANONYMIZE DS solves an industry-wide problem of balancing this need while maintaining the data's utility," says Weingarden. "TrialAssure is one of the first groups to automate the anonymization of datasets, and we will continue to stay at the forefront of the market with new technology methods."
TrialAssure ANONYMIZE DS:
- transforms original data into anonymized data using industry-standard techniques that can be reused and customized for each dataset
- assigns a risk score associated with the re-identification of this data based on thresholds set by the sponsor
- is entirely configurable to sponsor specifications
- was built from the ground up with input from data experts, and
- drives efficiency with modern machine learning technology in mind.
"The pharmaceutical industry is moving towards sharing data more openly. Health authorities and scientific journal editors alike may require greater levels of data transparency in the not-so-distant future," says Mohamad Zahreddine, CIO, TrialAssure, and member of the Forbes Technology Council. "Sharing this patient-level data for greater consumption will only improve the Good Pharma Scorecard for any company that uses our software."
With a simple design and rule builder function, ANONYMIZE DS saves sponsors time by allowing users to build a library of custom, reusable variables and reapply the same anonymization rules across studies. This saves valuable time and resources, especially with larger drug development pipelines where multiple studies share the same variables. As the library continually develops, the process becomes more efficient.
Once a sponsor determines which data fields to anonymize, the software will perform an analysis and assign a risk score. This analysis can be saved and replicated for future use, making the decision-making process easier.
ANONYMIZE DS is part of a fully-integrated suite of transparency tools, allowing information to be shared among health authorities without compromising patient privacy. "In the age of big data, research organizations can leverage pre-existing, anonymized data to speed-up the development process for life-changing medicines," Zahreddine adds.
TrialAssure ANONYMIZE DS is now available to select sponsors for limited release, with full deployment scheduled for fall 2019. To be part of the limited release, submit an inquiry at www.trialassure.com/contact-us
About TrialAssure
TrialAssure is a global clinical trial disclosure and transparency reporting suite with unmatched experience in helping clients navigate complex regulatory submission and reporting challenges. TrialAssure helps meet regulatory compliance goals through a flexible, scalable, and streamlined platform that regularly adapts to ever-changing clinical trial disclosure requirements. Established in 2009, TrialAssure was built from the ground up as a single, integrated transparency system, and it is continually strengthened by the experience of leading pharmaceutical industry compliance experts. For more information, visit: www.trialassure.com.
Media contact
Don McLean
+1-734-245-0165
[email protected]
SOURCE TrialAssure
Share this article